Contact: |
|
|
Michael Ostrach |
|
|
Chief Business and Principal Financial Officer |
|
|
510-665-7257 |
|
|
mostrach@dynavax.com |
|
|
DYNAVAX REPORTS FIRST QUARTER 2014
FINANCIAL RESULTS
BERKELEY, CA – May 5, 2014 – Dynavax Technologies Corporation (NASDAQ: DVAX) today reported financial results for the first quarter ended March 31, 2014. The Company had $177.7 million in cash, cash equivalents and marketable securities as of March 31, 2014.
For the quarter ended March 31, 2014, Dynavax reported total revenues of $3.5 million compared to $2.1 million for the first quarter of 2013. This increase primarily relates to the recognition of revenue under our collaboration agreement with AstraZeneca.
General and administrative expenses were $4.2 million for the quarter ended March 31, 2014 compared to $8.8 million for the first quarter of 2013. The 2013 three month period includes non-recurring cash and non-cash stock-based severance costs of $2.5 million. Excluding these non-recurring organizational transition costs, general and administrative expenses decreased by 34% in the first quarter of 2014 compared to the first quarter of 2013.
Research and development expenses were $13.2 million for the quarter ended March 31, 2014 compared to $14.2 million for the first quarter of 2013. This decrease was primarily due to higher severance expenses, including non-cash stock-based compensation charges, in the 2013 period.
About Dynavax
Dynavax, a clinical-stage biopharmaceutical company, discovers and develops novel vaccines and therapeutics in the areas of infectious and inflammatory diseases and oncology. Dynavax's lead product candidate is HEPLISAV, a Phase 3 investigational adult hepatitis B vaccine. For more information visit www.dynavax.com.
DYNAVAX TECHNOLOGIES CORPORATION
CONSOLIDATED STATEMENTS OF OPERATIONS
(In thousands, except per share amounts)
(Unaudited)
|
| Three Months Ended March 31, |
| ||||
| 2014 |
|
| 2013 |
| ||
Revenues: |
|
|
|
|
|
|
|
Collaboration revenue | $ | 2,373 |
|
| $ | 883 |
|
Grant revenue |
| 1,125 |
|
|
| 760 |
|
Service and license revenue |
| - |
|
|
| 442 |
|
Total revenues |
| 3,498 |
|
|
| 2,085 |
|
|
|
|
|
|
|
|
|
Operating expenses: |
|
|
|
|
|
|
|
Research and development |
| 13,231 |
|
|
| 14,164 |
|
General and administrative |
| 4,157 |
|
|
| 8,800 |
|
Unoccupied facility expense |
| 77 |
|
|
| - |
|
Total operating expenses |
| 17,465 |
|
|
| 22,964 |
|
|
|
|
|
|
|
|
|
Loss from operations |
| (13,967 | ) |
|
| (20,879 | ) |
|
|
|
|
|
|
|
|
Interest income |
| 65 |
|
|
| 72 |
|
Interest expense |
| - |
|
|
| (32 | ) |
Other income |
| 62 |
|
|
| 14 |
|
|
|
|
|
|
|
|
|
Net loss | $ | (13,840 | ) |
| $ | (20,825 | ) |
|
|
|
|
|
|
|
|
Basic and diluted net loss per share | $ | (0.05 | ) |
| $ | (0.11 | ) |
|
|
|
|
|
|
|
|
Shares used to compute basic and diluted net loss per share |
| 262,826 |
|
|
| 182,847 |
|
DYNAVAX TECHNOLOGIES CORPORATION
SELECTED BALANCE SHEET DATA
(In thousands)
(Unaudited)
|
| March 31, |
|
|
| December 31, |
|
Assets |
|
|
|
|
|
|
|
Cash, cash equivalents and marketable securities | $ | 177,679 |
|
| $ | 189,376 |
|
Property and equipment, net |
| 8,584 |
|
|
| 8,706 |
|
Goodwill |
| 2,576 |
|
|
| 2,579 |
|
Other assets |
| 4,746 |
|
|
| 3,961 |
|
Total assets | $ | 193,585 |
|
| $ | 204,622 |
|
|
|
|
|
|
|
|
|
Liabilities and stockholders’ equity |
|
|
|
|
|
|
|
Deferred revenues | $ | 10,334 |
|
| $ | 7,298 |
|
Other liabilities |
| 9,398 |
|
|
| 11,030 |
|
Total liabilities |
| 19,732 |
|
|
| 18,328 |
|
Stockholders’ equity |
| 173,853 |
|
|
| 186,294 |
|
Total liabilities and stockholders’ equity | $ | 193,585 |
|
| $ | 204,622 |
|